Using leptin for preventing overweight and compositions containing leptin

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to dietology, and can be used for preparing a food composition for infant feeding. That is ensured by adding leptin to the food composition as an additive in an amount of 0.1 and 30 mcg/l of this composition.

EFFECT: invention provides prevention of overweight and/or obesity-related complications at any age after finished breast feeding.

12 cl, 4 tbl, 3 ex

 

The technical field

The present invention relates to the field of weight control with compounds that prevent overweight.

The background to the present invention

Overweight is a violation, the percentage of which is constantly increasing in developed countries, and indeed is an important issue not only from an aesthetic point of view, but also poses a risk to human health, and is also the source of other social and economic problems. Excess body weight is associated with a high risk of complications, such as respiratory disease, heart disease, diabetes, hypertension, etc.

Leptin is involved in the transfer of one of the most important signals that contribute to the maintenance of body weight, and is a circulating protein encoded by the gene (s), which was identified and cloned in 1994 (Zhang y, Proenca R, Maffei m, Barone m, Leopold L. and J.M. Friedman, Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-423 (1994)). Leptin is mainly expressed in adipose tissue. At the initial stage of the study it was thought that leptin is antiserum hormone, as in animals with mutant genes s, that is, in animals whose genes s no leptin, develops obesity and diabetes. For example, mouse, s/s, have no mites is h, refer to the phenotype of obesity and diabetes. If such mice injected with leptin, they observed a decrease in feed intake and an increase in energy consumption that, in turn, leads to lower body fat and lower levels of circulating glucose and insulin. Consequently, these mice and other animal models, leptin exerts the function of regulating the amount of fat in the body. Indeed, the level of this protein in the plasma depends on fat mass in mice and humans, but in practice the introduction of leptin to obese people in most cases is not effective.

It is known that the action of leptin, released in the bloodstream in amounts proportional to fat mass, at the level of Central nervous system, mainly due to signal transmission in the hypothalamus about the level of fat reserves. Then leptin due to a combination of effects that it has on the Central and peripheral system, regulates the appropriate rate of consumption and the degree of energy that helps maintain the quantity of body fat within a certain range. However, most people with obesity were resistant to the direct action of leptin, which is produced mainly in adipose tissue. Despite the proven weight loss and normalizes the Yu metabolic abnormalities in the gene at the introduction of the hormone, in most cases, obesity is the introduction of the hormone has no direct effect.

It is now established that despite preliminary data about the adipocytes are the main source of leptin, the hormone is synthesized in other non-fat tissues such as the placenta, the epithelium of the mammary gland, skeletal muscle and stomach (see Smith-Kirwin S.M., O'connor D.M., De J. Johnston, Lancey E.D., Hassink S.G. and Funanage V.L., Leptin expression in human mammary epithelial cells and breast milk, J. Clin Endocrinol metab, 83: 1810-1813 (1998); Wang J., Liu R., Hawkins m, Barzilai N. and L. Rossetti A nutrient-sensing pathway regulates leptin gene expression in muscle and fat, Nature 393: 684-688 (1998)). It is now established that in addition to the actions of leptin on the processes that regulate body weight, leptin exerts many other functions: identifying periods of fasting and start the adaptation process of metabolism, which regulate the reproduction and the immune system, and effects on other endocrine and neural mechanisms.

Noteworthy is the fact that nairboi leptin is produced in significant quantities in the stomach of adult rats and humans, as well as in the epithelium of the mammary gland, as leptin is present in human milk (Casabiel X. and others, the Presence of leptin in the colostrums and/or breast milk from lactating mothers: a potential role in the regulation of neonatal food intake, J Clin Endocrinol Metab 82: 4270-4273 (1997)). Leptin is also present in the stomach of rodents in the prenatal and neonatal periods, although the e is synthesized by endogenous mechanism, but comes from the mother's body and respectively from the cells of the amniotic fluid and breast cells from which it is emitted and absorbed immature mucous membrane of the stomach. Indeed, only two weeks after birth the production of endogenous leptin prevails over the leptin obtained from external sources.

The obtained data suggest that leptin plays an important role in the early stages of life of a newborn as a component of breast milk, but it is now known that despite its role in maintaining an appropriate weight control, in the literature there are no data on the precautionary action of leptin on the growth of the body mass after its introduction in the medium and long terms.

Description of embodiments of the invention

The present invention relates to the use of leptin to obtain a composition intended for feeding infants and children up to adolescence, and these compositions contain leptin in more than 50 ng/kg to prevent excess body weight and/or complications related to the specified state in later years. As specified leptin use of recombinant leptin, which can be obtained from various sources, including che is oweka, and use polnocennoi recombinant leptin or partially hydrolyzed leptin. The term "partially hydrolyzed leptin" means any fragment specified molecules, which preserves the functional properties of leptin.

The present invention also relates to the use of leptin to obtain the drug composition, and this composition is the product of baby food.

In addition, the present invention relates to the use of specified food composition, which is characterized by the fact that the specified composition was prepared in the form of powdered milk for infant feeding or breast milk substitutes for feeding children. In a preferred embodiment of the invention specified food composition is a toothpaste or baby food or advanced composition. In these cases, the food composition contains leptin at a concentration of from 0.1 to 30 μg/l of milk. In a preferred embodiment, the specified concentration of leptin is 2.5 ág/l

On the other hand, the object of the present invention is the application of food composition and food composition was prepared in the form of baby food or food supplements for feeding children. In addition, the present invention is characterized by the fact that the food composition in any e the form includes a daily dose of leptin in the range from 25 up to 60,000 ng. In a preferred embodiment of the present invention indicated a dietary Supplement contains a daily dose of 1650 ng in the first month of life, 2300 ng during the second month and 2650 ng during the third to fifth months.

Specified food additive is chosen from liquid food composition (syrup or beverage and solid food composition (oral food tablet, oral food capsule or soluble powder).

On the other hand, the present invention relates to a food composition for feeding infants and children up to adolescence, which includes leptin in more than 50 ng/kg of the composition or provides the daily dose of leptin than 25 ng.

In a preferred embodiment, the specified composition was prepared in the form of baby food or powdered milk for feeding infants, or liquid composition of breast milk for feeding infants, or in the form of paste or baby food, or improved milk composition. In the most preferred embodiment, the food composition contains leptin at a concentration in the range from 0.1 to 30 μg/l of milk and preferably 2.5 ág/l

In another preferred embodiment, the specified composition was prepared in the form of food supplements for feeding children, which provides a daily dose of leptin from 25 what about 60000 ng. Preferably specified dietary Supplement provides the daily dose of leptin 1650 ng in the first month of life, 23000 ng during the second month and 2650 ng during the third to fifth months of life.

In a preferred embodiment, the specified dietary Supplement for babies receive in the form of liquid food composition selected from the syrup or beverage, or in the form of a solid food composition selected from the following forms: pressed tablet, oral tablets, oral capsules and dissolve the powder.

In other words, the food composition includes leptin, which preferably is recombinant leptin from various sources, for example polecany recombinant leptin or partially hydrolyzed leptin.

Variant implementation of the present invention

The results obtained in laboratory tests on mice, can be generalized to humans and other animal species. These results suggest that for the first time with the introduction of leptin oral during breast-feeding period had the opportunity to protect the subject from the increase of overweight in childhood (as in the case of reception by superchlorinate diet and standard diet).

The results of the main experiments are described in detail below.

Experiment 1

The study of absorption Latinamerican epithelium of the stomach and the possible functional effect

Preliminary experiments involved the introduction of a single dose of leptin newborn rats at the stage of feeding breast milk to determine the degree of absorption of leptin and evaluation of its physiological action on rats at the stage of feeding mother's milk. This experiment indicated the absorption of leptin on the functional mechanism. Then there was another experiment, which included a dose of leptin newborn rats throughout the period of feeding mother's milk (21 days). After this period, rats were scored to determine the additional physiological effect of dietary leptin compared with that found in mother's milk at an early stage of development, preferably on consumption or body weight.

During the first stage of the experiment and to evaluate the absorption of leptin single dose of leptin was administered orally in accordance with five daily consumption of leptin contained in breast milk, rats aged 4 days, and then rats were selected samples of blood and stomach before and after injection of the indicated dose. The concentration of leptin in the blood samples and stomach were determined by ELISA. After 1 h after administration of oral doses of leptin to rats at the age of 4 days leptin levels in the blood and stomach increase (see table 1)that svidetelstvo is about the absorption of leptin immature epithelium of the stomach. This leptin has an effect, as consumption is reduced.

Weight of stomach contents and the amount of leptin found in the serum and in the stomach of the control rats at the age of 4 days and in rats that were administered a single oral dose of leptin through 1 h after injection (used rats from 5 different litters and the values obtained for each litter, expressed in percentage, in each case compared with the control, the results are presented as mean values ± standard deviation ()).

Table 1

Control ratsThe rat after injection of leptin
Stomach contents (%)99,93±9,866,11±11,54*
Leptin in serum(%)100,05±9,98200,24±20,96*
Leptin in the stomach (%)100,04±16,73173,11±17,71*
* statistical significance compared to control rats

Newborn rats used for the experiment, was introduced during the stage of feeding mother's milk (for PE is o 21 days after birth) a single oral dose of leptin, equivalent to five times the daily consumption of leptin contained in breast milk. These animals were scored at the completion of the period of feeding mother's milk. Leptin was administered by oral pipette in the period 1-20 days of feeding mother's milk, during the first two hours of the light cycle. Control rats received excipient (water). As leptin used recombinant rat leptin. The number of introduced animals leptin was increased in the first day from 1 ng to 43.5 ng at day 20. This dose was calculated as five times the amount of leptin consumed daily of milk, which, in turn, was calculated taking into account the concentration of leptin in breast milk (pre-calculated according to the group of 10 lactating rats at three different stages of feeding breast milk at day 7, 14 and 21) and taking the calculated total daily consumption of milk during the feeding period milk, as described in article Kojima, T., Nishimura, M., Yajima, T., Kuwata, T., Suzuki, Y., Goda, T., Takase, S. and Harada, E., Effect of intermittent feeding on the development of disaccharidase activities in artificially reared rat pups, Comp Biochem Physiol A Mol Integr Phsyiol, 121: 289-297 (1998)).

These animals were collected serum samples and stomach. The content of endogenous leptin found in the stomachs of young rats receiving oral exogenous lepti the period of feeding mother's milk, reduced in comparison with the amount of leptin found in the stomachs of control animals. The contents of the stomach in rats treated with leptin, also decreases. As for the content of leptin in the stomach, there was a significant reduction of this magnitude in rats treated with leptin, 23%, i.e. from 1,080±0,073 g to 0,831±0,031, the Treatment has no effect on body weight.

Therefore, we can conclude that with the introduction of exogenous leptin is its absorption in the stomach during feeding mother's milk and that leptin influences the endogenous production of leptin and further reduces feed intake. Therefore, it is possible that leptin will affect body weight in adulthood.

Experiment 2

The study of the actions of leptin in his introduction to the breastfeeding mother's milk on body weight in adult rats aged 12 weeks

After confirming the data on absorption of leptin when it is orally administered to a breastfeeding mother's milk in its functional form in immature stomach newborn rats, the authors conducted another experiment to determine the potential effect of additional quantity of food leptin during feeding breast milk to increase body mass in adult animals.

10 newborn rats one SIP is the one distributed by randomization into two groups: a control group and a group treated with leptin. Animals during feeding breast milk from 1 to 20 days oral introduced by pipette 20 µl of excipient (water) or recombinant leptin rats. The number entered leptin was increased from 1 ng per day 1 to 43,8 ng at day 20 (see experiment 1). This dose was calculated taking into account five times the number of leptin consumed daily of milk, which, in turn, was calculated taking into account the concentration of leptin in breast milk (pre-calculated according to the group of 10 lactating rats at three different stages of feeding breast milk at day 7, 14 and 21) and taking the calculated total daily consumption of milk during the feeding period milk, as described in article Kojima, T., Nishimura, M., Yajima, T., Kuwata, T., Suzuki, Y., Goda, T., Takase, S. and Harada, E., Effect of intermittent feeding on the development of disaccharidase activities in artificially reared rat pups, Comp Biochem Physiol A Mol Integr Phsyiol, 121: 289-297 (1998)). In the experiment used male rats.

At day 21 after weaning babies from maternal nipple control rats and rats treated with leptin, were divided into two groups: normolipidemic group that received standard dry food (3.8 kcal/g), in which 10% of calories is fat, and hyperlipidemia group that received dry food (4.7 kcal/g), in which 45% of the calories is fat.

Body weight and feed consumption register is listed three times per week during the period from the day of weaning to 12 weeks. Throughout the experiment complied with all instructions and requirements for the care and use of laboratory animals, developed at the University de Ie Illes Balears.

At the age of 12 weeks in rats no significant action treatment with leptin in the breastfeeding mother's milk on body weight in adult rats in both groups: in the group treated normolipidemia diet or in the group of rats treated with hyperlipidemia diet (see table 2, some examples), and therefore, the registration body mass continued for a longer period. It should be noted that in rats, some litters that received leptin, there is a slight tendency for the weight loss.

Body weight of male rats aged 12 weeks in the control group and in the group treated with leptin during feeding mother's milk. Presents two specific examples for individuals from the same litter (1-2 specimens per group). Also shown are average values for animals of all five litters. The results are presented as mean values±.

Table 2

Normolipidemia
DietThe treatmentWeight-for litter 1(g)Weight-for litter 2 (g)Average values for animals of all 5 litters
Control392359375±14
Leptin392325364±13
HyperlipidemiaControl416415412±16
Leptin414377392±6

Experiment 3

The study of the actions of leptin in his introduction to the breastfeeding mother's milk on body weight of adult animals at the age of 25 weeks

This experiment was performed under similar conditions as described in experiment 2, but the time of registration body mass was extended until the rats of 25 weeks of age. In this age in rats treated with an additional amount of leptin in the breastfeeding mother's milk, reduced body weight compared with control rats for the treated group normolipidemia diet, and for the treated group hyperlipid diet, although treated rats hyperlipid diet, there is a more significant effect (see table 3, some examples). Taking into account what bsic data obtained in rats from all litters, it should be noted that the reduction of body weight in rats treated with leptin and normolipidemia diet, approximately 7%, and in rats treated with leptin and hyperlipidemia diet, is 8%. This reduction is of great importance, since it is known that even a small weight loss (especially in subjects with obesity) has a positive effect on the condition of the subject, first of all, there is a decrease in opportunities for the development of secondary complications associated with obesity.

It should be noted that animal some litters leptin has a more significant effect than other litters, which is probably due to the concentration of leptin, already present in breast milk, and that the dosage injected during the experiment leptin should be selected in the appropriate limits.

Body weight of male rats at the age of 25 weeks in the control group and in the group treated with leptin during feeding mother's milk. Presents two specific examples for individuals from the same litter (1-2 specimens per group). Also shown are average values for animals of all five litters. The results are presented as mean values±.

Table 3

Diet The treatmentWeight-for litter 1 (g)Weight-for litter 2 (g)Average values for animals of all 5 litters
NormolipidemiaControl540481528±21
Leptin519479492±17
HyperlipidemiaControl595564572±17
Leptin525506526±10
*Statistical significance compared with the value obtained for control rats fed a diet similar to the diet of rats treated with leptin.

The results obtained indicate that recombinantly food leptin entered perorally, influences, showing a possible role in preventing the buildup of body weight in the period after the maturity of the subjects. In addition, it can be concluded that the effect that the products partially the CSOs digestion leptin (hydrolysis products), since leptin enters the digestive cavity, where it is partially digested.

Therefore, I believe that you can use food preparations containing recombinant leptin of milk specific to different species, as in the form polnocennogo protein, in the form of a partially hydrolyzed protein. It is also recommended to use leptin from the same species of animal, which is to be included in the diet of these foods, however these guidelines do not limit the scope of the invention as it is possible to use leptin from one species for inclusion in food products intended for inclusion in the diet of other species.

Due to the above the following example is presented only to illustrate the present invention and does not restrict the scope of the invention.

The example of milk containing the additive leptin

The composition "milk is for babies" (infant milk) meets food for children during the first 4-6 months of life. Specified milk for infants is characterized by the energy density in the range from 60 to 75 kcal/100 ml, and it consists of the following components: proteins, lipids, carbohydrates, minerals and vitamins, as indicated in table 4 (for a detailed description of the composition, see Official Journal of the European Communities, N Is L 175, p.40-42 (4. 7, 1991)).

Table 4

Vitamin K
ComponentEnergy value (lower and upper limits)Component type
Proteins2,25-3 g/100 kcalThe proteins of milk cows
Soybean protein
Carbohydrates3,3-6.5 g/100 kcalLactose
Maltose
Sucrose
Maltodextrins
Glucose syrup
Starch
Minerals20-60 mg/100 kcalSodium
60-145 mg/100 kcalPotassium
50-125 mg/100 kcalChlorine
50 mg/CACalcium
25-90 mg/CAPhosphorus
5-15 mg/100 kcalM the wrath
0.5-1 mg/100 kcalIron
0.5-1 mg/100 kcalZinc
20-80 µg/100 kcalCopper
5 µg/100 kcalIodine
Vitamins60-180 mg/100 kcalVitamin a
1-2,5 µg/100 kcalVitamin D
40 µg/100 kcalThiamine
60 µg/100 kcalRiboflavin
250 µg/100 kcalNicotinamide
300 µg/100 kcalPantothenic acid
35 µg/100 kcalVitamin B6
1.5 mcg/100 kcalBiotin
4 µg/100 kcalFolic acid
0.1 ág/100 kcalVitamin b 12
8 µg/100 kcalVitamin C
4 µg/100 kcal
0.5 mg/g of linoleic acidVitamin E

According to the present invention leptin add as a Supplement to the specified composition of milk to a concentration of 2500 ng/l, or 2.5 ág/l

A similar technique can be used to obtain an improved composition of milk (for a detailed description of the composition, see Official Journal of the European Communities, N° L 175, p.40-42 (4. 7, 1991)).

1. The use of leptin to obtain food composition for feeding infants, characterized in that the composition comprises leptin as an additive in amounts of between 0.1 and 30 g/l of the composition, and its use for the prevention of overweight and/or development of complications of this condition at any age after completion of the feeding of breast milk.

2. The use of leptin according to claim 1, characterized in that the quality of leptin use of recombinant leptin.

3. The use of leptin according to claim 1, characterized in that the use of leptin derived from the human body.

4. The use of leptin according to claim 1, characterized in that the quality of leptin use a partially hydrolyzed recombinant leptin.

5. The use according to claim 1, characterized in that the quality of food composition use food for children.

6. The use according to claim 1, ex is different, however, what food composition selected from the group including powdered milk for infant feeding, liquid human milk for infant feeding, pasta for feeding solid composition for feeding infants and advanced composition.

7. The use according to claim 1, characterized in that the food composition contains leptin at a concentration of 2.5 ág/l

8. The use according to claim 1, characterized in that, as specified food compositions used dietary Supplement for children.

9. The use according to claim 1, characterized in that the said food composition provides a daily intake of leptin from 25 up to 60,000 ng.

10. The use according to claim 1, characterized in that the specified dietary Supplement for children is chosen from the group comprising liquid food composition and solid food composition.

11. The use according to claim 1, characterized in that the said food composition is a liquid composition which is selected from the syrup and drink.

12. The use according to claim 1, characterized in that the said food composition is a solid composition which is selected from oral food tablets, oral nutritional capsules and dissolve the powder.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely therapy of pulmonary tuberculosis. A method of treating pulmonary tuberculosis consists in introducing Bestim with underlying anti-tuberculosis preparations, and Bestim is introduced intratracheally in dose 1.0 mg 3 times a week; total therapeutic course makes 6 introductions. The preparation escaping a liver gets in the beginning to lungs and stays there for some time due to an ability of interstitial pulmonary tissue to keep medical substances quickly absorbed in pulmonary tissue. The efficacy of the integrated anti-tuberculosis treatment involving the intratracheal introduction of Bestim is increased: within the time limits to 2 months during an intensive phase of chemotherapy bacterioexcretion is terminated in 90.9 % vs. 50.1 % of control group (p<0.01) and the cavities are closed 50.0 % of patients vs. 27.0 % of control group. The main group shows 100% recovery of nonspecific endobronchitis. A cytokine imbalance is restored due to decreasing levels of proinflammatory cytokines (α -TNF (p <0.05) and γ-interferon), tends to increasing a level of anti-inflammatory cytokine IL-4.

EFFECT: method provides fast absorption of the preparation Bestim and delivery first of all into the lymphatic pulmonary system, then into the lesser circulation and only then into the greater circulation.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new phospholipid curcumine complexes or to extracts containing it exhibiting improved bioavailability. The phospholipid curcumine complex or the extract containing it in which a phospholipid is a soya phospholipid and the phospholipid to parity to curcumine ratio is found within the certain range. A method for preparing the phospholipid complex. The phospholipid curcumine complex or the extract containing it prepared by the method described above. A pharmaceutical composition containing the phospholipid complex exhibiting chemoprophylactic activity. Using the phospholipid complex for preparing chemoprophylactic agents.

EFFECT: phospholipid complexes exhibit the improved bioavailability.

7 cl, 1 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, namely neurooncology and may be used for treating benign cerebral tumours. That is ensured by using 4-methyl-3-[[4 (3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide and its N-oxide or pharmaceutically acceptable salt for preparing a pharmaceutical composition.

EFFECT: group of inventions allows treating benign cerebral tumours, particularly neurofibromatoses by means of inhibiting both signal pathways involving PDGFR and Kit receptors.

7 cl, 1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, more specifically an antimicrobial pharmaceutical gel of laevomycetin. The presented gel contains laevomycetin (0.1-15.0 wt %) and excipients: propyleneglycol - 10.0-40.0 wt %, UV filter Escalol 567 - 1.0-40.0 wt %, cyclomethicone DC 345 - 5.0-20.0 wt %, organosilicone emulsifier DC 5329 - 1.0-4.0 wt %, organosilicone elastomer DC 9045 - 5.0-60.0 wt %, antioxidant Tinogard NOA - 0.02-0.1 wt %, acrylate emulsion of copolymer Salcare SC80 - 1.0-3.5 wt %, trometamol - 1.0-2.5 wt %, preservative Sharomix MCI 0.1-0.5 wt %, purified water to 100.0 wt %.

EFFECT: due to said composition of excipients the invention provides laevomycetin penetration in deep skin, skin protection against ultra-violet radiation and improved gel stability.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, more specifically a pharmaceutical gel exhibiting antimicrobial and antifungal action. The presented gel contains as active ingredients betamethasone dipropionate (0.01-0.3 wt %), gentamycin sulphate (0.02-0.6 wt %) and terbinafine hydrochloride (0.8-5.0 wt %), and as excipients - propylene glycol (10.0-40.0 wt %), UV filter Escalol 567 (1.0-40.0 wt %), cyclomethicone DC 345 (5.0-20.0 wt %), organosilicone emulsifier DC 5329 - (1.0-4.0 wt %), organosilicone elastomer DC 9045 (5.0-50.0 wt %), antioxidant Tinogard NOA (0.02-0.1 wt %), acrylate emulsion of copolymer Salcare SC80 (1.0-3.5 wt %), trometamol (1.0-2.5 wt %), preservative Sharomix MCI (0.1-0.5 wt %), purified water (to 100.0 wt %).

EFFECT: due to said composition of excipients the invention provides skin protection against ultra-violet radiation and improved penetration of active ingredients in derma.

3 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, more specifically a pharmaceutical gel exhibiting antimicrobial and antifungal action. The presented gel contains as active ingredients betamethasone dipropionate (0.01-0.3 wt %), gentamycin sulphate (0.02-0.6 wt %) and terbinafine hydrochloride (0.8-5.0 wt %), and as excipients - propylene glycol (10.0-40.0 wt %), UV filter Escalol 567 (1.0-40.0 wt %), cyclomethicone DC 345 (5.0-20.0 wt %), organosilicone emulsifier DC 5329 - (1.0-4.0 wt %), organosilicone elastomer DC 9045 (5.0-50.0 wt %), antioxidant Tinogard NOA (0.02-0.1 wt %), acrylate emulsion of copolymer Salcare SC80 (1.0-3.5 wt %), trometamol (1.0-2.5 wt %), preservative Sharomix MCI (0.1-0.5 wt %), purified water (to 100.0 wt %).

EFFECT: due to said composition of excipients the invention provides skin protection against ultra-violet radiation and improved penetration of active ingredients in derma.

3 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: declared group of inventions refers to veterinary virology and concerns a peptide-like compound showing the antiviral properties, and also a method for preparing it. That is ensured by synthesis at 22°C for 24 h and molar ratio of the following components: 1,12-dodecanediamine - ethyldiisopropylamine - N-hydroxysuccine imide ester N"б", NIm-di-tert-butyloxycarbonyl-L-histidine 2.3: 5.1: 5.1 in ethylacetate as a solvent, N, N-dimethylethylene diamine added to a reaction mixture (1 mole, 110 mcl) and mixed for 30 min, then sequentially washed out in 2 % citric acid (20 ml), water (20 ml), saturated solution NaHCO3 (20 ml) and water (20 ml); the solvent is removed in vacuum, by dissolving the rest of the mixture "ТФУ":CH2Cl2=1:1 (5 ml); the reaction mixture is kept for 1 h at room temperature, protective groups are removed by trifluoroacetic acid in vacuum, and the rest is boiled off with ethanol (3×10 ml).

EFFECT: peptide-like compound allows extending the range of antiviral agents for treating and preventing cattle viral diseases with reliable reduction of virus reproductions due to stability of the chemical compound and preserved antiviral activity for 2 years.

2 cl, 3 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and may be used for treating patients with hypertension and lipid storage disease. There is applied a combined drug containing dihydropyridine, calcium canal blockers, and statin, a hypolipidemic agent. The drug is prepared in such a manner that release rate of said ingredients can be controlled with respect to each other.

EFFECT: method allows higher clinical effectiveness and compliance, prevented antagonist and side effects of the combined therapy.

27 cl, 12 tbl, 10 dwg, 7 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, oncology and haematology, and may be used for determining cardiotoxic complications in patients suffering chronic lymphatic leukemia and treated with polychemotherapy. Patient's blood serum is examined, and if observing no signs of infectious-inflammatory process and haemolysis, then blood is examined for lactate dehydrogenase by standartised UV test at temperature 37°C; the lactate dehydrogenase isoenzyme ratio is shown by enzyme electrophoresis, while enzyme linked immunosorbent assay provides calculating a tumour necrosis factor-α level. The examinations and assays run in with introducing chemopreparations and repeated in a week following the introduction and further throughout the whole polychemotherapeuty course in the same regiment, and in the end of the therapeutic course - once a month during the whole follow-up period. The lactate dehydrogenase level increasing by more than 510 IU/l and tumour necrosis factor-α increasing by more than 35 pg/ml, the lactate dehydrogenase-1 to lactate dehydrogenase-2 ratio increasing by more than 1 give evidence of potential development of cardiotoxicity of the chemopreparations in the patients, and subsequently, of life-threatening rhythm disturbances.

EFFECT: method enables well-timed, early determination of developing cardiotoxic complications of the chemotherapy in the given group of patients.

1 ex

FIELD: medicine.

SUBSTANCE: polypeptide (versions) immunogenic with respect to meningococcal infections contains: an amino acid sequence at least 90 % identical to a sequence presented in the description (SEQ ID NO: 32), or said amino acid sequence, or a fragment of 80 sequenced amino acids of said sequence. What is described is an antibody which contacts with the polypeptide under the invention and which may be used as a drug. What is described is nucleic acid of the preset structure which codes the polypeptide or its versions and which may be used for treating or preventing a disease and/or an infection caused by Neisseria meningitides. The invention provides additional polypeptides applicable in advanced vaccines for preventing and/or treating meningococcal meningitis. The peptides can also find application in diagnosing of the disease and as targets of antibiotics.

EFFECT: higher clinical effectiveness for meningococcal meningitis.

19 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely resuscitation, and may be used for the purpose of treating the patients suffering a severe combined craniocerebral injury (CCI). That is ensured by a standard conventional intensive care. It is added with the intravenous bolus administration of the preparation Epocrin. Within the first day of the posttraumatic period, Epocrin 10000 IU is administered in a single dose. On the second say of the posttraumatic period, Epocrin 10000-20000 IU is administered with regard to the injury severity and threatening death. On the third and fourth days, Epocrin 10000 IU is administered. On the fifth posttraumatic day, Epocrin is administered in dose 5000-10000 IU.

EFFECT: developed dose schedule included in the intensive care of the combined severe CCI patients enables higher clinical effectiveness, reduced death rate and complication rate.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutics. A method involves internal introduction of an effective amount of N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide into a human. Major depression involves at least one symptom selected from a group consisting of: permanent sadness, anxiety or indifference; a feeling of despair; pessimism; a feeling of remorse, uselessness or helplessness; loss of interest or pleasure of passions and actions previously delighted, including sex; lower power, fatigue or inhibited existence; concentration, memory or decision-making problems; insomnia, very early awakening or oversleeping; loss of appetite and/or weight or overeating and weight gain; death and suicide thoughts; attempted suicides; restlessness; impatience; persistent unresponsive physical symptoms including headache, dyspepsia and chronic pain, and any combination thereof.

EFFECT: method provides effective prevention and treatment of major depression symptoms.

2 cl, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to conjugates of a polypeptide and an oligosaccharide or its pharmaceutically acceptable salt in which the polypeptide is conjugated to at least one oligosaccharide-spacer residues; the oligosaccharide represents a synthetic sulphated pentasaccharide residue and substantially shows affinity for antithrombine III, and the spacer shows a bond and is substantially a pharmacologically inactive flexible cross-link residue.

EFFECT: conjugates of the present invention have improved pharmacokinetic properties in comparison with appropriate unconjugated polypeptides.

13 cl, 24 dwg, 7 tbl, 28 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and can be used in protection of organism against mutagenic impact of heavy metals in experiment. Method includes introduction into organism of medication "Melaxen" in dose from 5.25·10-7 mg to 21.0·10-7 mg per 100 g of live weight as antimutagenic substance daily during 3-7 days before sleeping at cadmium background.

EFFECT: application of invention makes it possible to extend arsenal of means for reduction of mutagenic effect of cadmium.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and relates in particular to medication for women, which has contraceptive and protective action against inflectional diseases: herpes, HIV infections, viral disease. Medication for vaginal application, possessing contraceptive and protective against inflectional diseases action contains actively-acting components and target base. As actively-acting components medication contains contraceptive, bactericidal, anti-inflammatory preparations, and as target base it contains gel-forming biocompatible polymers and L-lysin hydrochloride with specified component ratio per 1 g. Medication presents gel, ointment, cream, liniment.

EFFECT: medication not only has contraceptive action, but also makes it possible to simultaneously prevent sexually transmitted infection diseases.

3 cl, 6 ex

FIELD: medicine.

SUBSTANCE: described are novel versions of erythropetine (EPO), representing deleted forms of hormone, which possess cytoprotective, in particular, neuroprotective, function, without, in fact, demonstrating hemopeotic activity, as well as their obtaining by method of recombinant DNAs and means requited for its realisation (vector constructions and host-cells).

EFFECT: claimed is application of novel EPO versions with cytoprotective action as active agent in manufacturing medicines for treatment or prevention of state, associated with tissue damage induced by cell death.

22 cl, 30 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention describes neuropeptide-2 receptor agonists of formula and also their pharmaceutically acceptable salts.

EFFECT: possibility of using the compounds for treating diseases, such as, eg obesity and diabetes.

11 cl, 25 dwg, 1 tbl, 44 ex

FIELD: medicine.

SUBSTANCE: method involves introduction in a period of premonitory signs, not later than after the first 6 hours of the symptoms of genital and urogenital herpetic infection, a combination of two antiviral preparations: allokin-alpha 1 mg, once a day, every second day, a therapeutic course of 3 subcutaneous injections and oral single dose of famciclovir 1500 mg, and also external therapy of infagel 2 times a day for 5 days.

EFFECT: use of the invention enables reducing formation of vesicles and urogenital mucosal erosions, decreasing length of recurrences and a prolonged intercurrent period.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to treating male patients suffering bronchial asthma early acquired androgen deficiency. That is ensured by a singular therapy 10 mg once a day combined with andriol 40 mg twice a day in the morning and in the evening. The therapeutic course makes 2 months.

EFFECT: potentiation of a bronchodilating effect of singular with no side effects.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncogynaecology, and can be used in treating initial endometrial cancer. The method involves administration of the release gonadotrophin agonist Lucrine-depot (RGn-A) combined with the intrauterine levonorgestrel release system Mirena (LNG-RS). In atypical endometrial hyperplasia (AEH), the RGn-A Lucrine-depot is introduced 3.75 mg 3 times every 28 days; a positive course of the disease requires the administration of the LNG-RS with underlying continuing therapy by the RGn-A 3.75 mg 3 times every 28 days, for the purpose of prevention of the recurrent disease, the LNG-RS is used for at least 6 months. In endometrial cancer (EC), the RGn-A 3.75 mg is introduced. once in 28 days in 3 injections; the positive course of the disease implies the administration of the RGn-A 3.75 mg once in 28 days in 5 injections; the third injection is followed by the administration of the LNG-RS for at least 1 year.

EFFECT: use of the invention allows providing higher clinical effectiveness in initial endometrial cancer in women of childbearing age, reducing length of treatment and rehabilitation in the patients, eliminating hormonotherapy associating complications - postinjection abscesses and thrombophlebitises.

2 ex

FIELD: food industry.

SUBSTANCE: inventions group relates to production of functional biologically active products of natural silk, in particular, of silk proteins which may be used in food, pharmaceutical and cosmetic industries. The method characterisation is as follows: Bombyx Mori mulberry silkworm cocoons are cut up for larvae removal, milled, placed into water and maintained for no less than 5 minutes. Then the soaked raw material is placed into a vessel and poured with water, incompletely filling the vessel, the weight ratio of the raw materials to water being (0.5-1.5):(4.5-5.5). Then the vessel is closed up, heated up to 200-300°C and maintained at that temperature during 10-90 minutes. Then one performs quick cooling to produce the end functional biologically active product in a solution form. Alternatively, the method envisages drying the produced solution till complete drying to produce a functional biologically active product in a powder form. The inventions group allows to simplify the process of preparation of a biologically active food product based on natural silk due to fewness of the process stages, exclusion of expensive reagents, hydrolysate preparation time reduction and simpler equipment usage.

EFFECT: ready products do not contain impurities and contain maximum quantity of active substances.

4 cl, 1 dwg, 2 ex

Up!